Sign in
AAPGV Stock Price, Chart, Stats & News
Ascentage Pharma Group International
Save
Ascentage Pharma Group International (AAPGV) does not currently pay a dividend.
127.31M
Market cap
–
Current P/E
–
Forward P/E
AAPGV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 84.09% |
Operating margin | -210.42% |
Pretax margin | -215.56% |
Net margin | -216.74% |
Effective tax rate | -0.56% |
ROA | -31.03% |
ROE | -123.61% |
D/E | 1.49x |
Interest coverage ratio | -46.34x |
AAPGV valuation
P/E | – |
P/S | 26.07x |
P/B | 11.13x |
P/CF | 60.67x |
P/FCF | 62.91x |
P/OCF | 60.67x |
PEG | -0.68x |
EV multiple | -13.74x |
About
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapeutic solutions for various cancers, chronic hepatitis B virus (HBV) infection, and age-related conditions, primarily within Mainland China. Its flagship product candidate, HQP1351, is a BCR-ABL inhibitor specifically designed to target BCR-ABL1 mutants, notably those harboring the T315I mutation. The company's extensive pipeline further comprises: APG-2575, an orally administered, selective Bcl-2 inhibitor for hematologic malignancies and solid tumors.
Similar securities
Based on sector and market capitalization
Report issue